enavatuzumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 457124199

| type = mab

| image =

| alt =

| mab_type = mab

| source = zu/o

| target = TWEAK receptor

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|CAS}}

| CAS_number = 1062149-33-0

| UNII_Ref = {{fdacite|changed|FDA}}

| UNII = 914910XFBB

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| C=6334 | H=9792 | N=1700 | O=2000 | S=42

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| KEGG = D09896

}}

Enavatuzumab is a humanized monoclonal antibody used in the treatment of solid tumors. It targets the TWEAK receptor.{{cite journal | vauthors = Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, Weiss GJ, Chadha M, Oey A, Ding HT, Culp PA, Keller SF, Zhao VY, Tsao LC, Singhal A, Holen KD, Von Hoff D | display-authors = 6 | title = Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors | journal = Molecular Cancer Therapeutics | volume = 17 | issue = 1 | pages = 215–221 | date = January 2018 | pmid = 29054986 | pmc = 5752572 | doi = 10.1158/1535-7163.MCT-17-0330 }}

Enavatuzumab was developed by Facet Biotech Corp.{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Enavatuzumab|publisher=American Medical Association|url=http://www.ama-assn.org/resources/doc/usan/enavatuzumab.pdf}}